MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional data from the completed SPRINT-MS Phase 2b trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS) will be presented in three separate presentations at the American Academy of Neurology (AAN) 71st Annual Meeting to be held May 4-10, 2019 in Philadelphia, Pennsylvania.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.